Cipla Forms Global Partnership for Cell Therapy Advancements
Cipla, a global pharmaceutical company, has revealed a partnership in the United States with Kemwell Biopharma and Manipal Education & Medical Group. The collaborative initiative aims to advance and bring to market innovative cell therapy products addressing critical unmet medical needs in the US, Japan, and the EU. Cipla (EU), the UK-based subsidiary of Cipla, will acquire a 35.2 percent stake in the newly established joint venture. This partnership will leverage Cipla's expertise in product development and commercialization, Kemwell's proficiency in biologics, and Manipal's healthcare delivery knowledge to accelerate the development, manufacturing, and distribution of cell therapies.
Umang Vohra, Managing Director and Global CEO of Cipla stated, "This joint venture reinforces our concerted efforts to move up the innovation curve and pioneer transformative treatments in the areas of stem cell and CAR T-cell therapies, enabled by advances in biotech, mRNA and cell-engineering research, that can make a difference to patient lives globally. As we steer Cipla into the future and lead with purpose, our partnership with Kemwell and Manipal Group will be integral in realizing these advancements".
Echoing the sentiment, Ranjan Pai, Chairman of Manipal Education & Medical Group, stated, "We are very happy to partner with Cipla and Kemwell in bringing the next generation of biological therapies to address unmet medical needs globally. We believe that Cell therapy products will be a game-changer in offering an advanced therapeutic treatment for millions of patients suffering from painful diseases".
Anurag Bagaria, Chairman and CEO of Kemwell, stated, "We believe that Cell therapies will become a major branch of medical treatment and will become a standard of care for challenging diseases. Kemwell has built a cGMP facility in Bangalore and made India an emerging hub for cell therapy development and manufacturing". This partnership represents the second joint venture between Cipla and Kemwell Biopharma, building on their earlier collaboration with the establishment of Aspergen in the USA in 2022. Aspergen is dedicated to the global development, manufacturing, and commercialization of biosimilars.
Umang Vohra, Managing Director and Global CEO of Cipla stated, "This joint venture reinforces our concerted efforts to move up the innovation curve and pioneer transformative treatments in the areas of stem cell and CAR T-cell therapies, enabled by advances in biotech, mRNA and cell-engineering research, that can make a difference to patient lives globally. As we steer Cipla into the future and lead with purpose, our partnership with Kemwell and Manipal Group will be integral in realizing these advancements".
Echoing the sentiment, Ranjan Pai, Chairman of Manipal Education & Medical Group, stated, "We are very happy to partner with Cipla and Kemwell in bringing the next generation of biological therapies to address unmet medical needs globally. We believe that Cell therapy products will be a game-changer in offering an advanced therapeutic treatment for millions of patients suffering from painful diseases".
Anurag Bagaria, Chairman and CEO of Kemwell, stated, "We believe that Cell therapies will become a major branch of medical treatment and will become a standard of care for challenging diseases. Kemwell has built a cGMP facility in Bangalore and made India an emerging hub for cell therapy development and manufacturing". This partnership represents the second joint venture between Cipla and Kemwell Biopharma, building on their earlier collaboration with the establishment of Aspergen in the USA in 2022. Aspergen is dedicated to the global development, manufacturing, and commercialization of biosimilars.
.jpg "Ensuring Compassionate Care Through Expert Clinical Research")
